GlassScriptPhysician profile
Arlene Edwards
NPI 1205466414
$3,693.16
in general payments reported to CMS, 2019-2025
11 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $1,179 · 2023: $1,095 · 2024: $525 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,606.56 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $509.02 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $461.68 | 2022-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $316.68 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.43 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $166.03 | 2021-2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $143.43 | 2021-2025 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $122.81 | 2022-2023 | Ingrezza |
| Novo Nordisk INC | $57.15 | 2023 | Wegovy |
| Abbvie INC. | $27.73 | 2022 | |
| Bioxcel Therapeutics, INC. | $18.64 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.